ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)

被引:23
作者
Loibl, S. [1 ,2 ,3 ,38 ]
Azim, H. A., Jr. [4 ]
Bachelot, T. [5 ]
Berveiller, P. [6 ,7 ]
Bosch, A. [8 ,9 ]
Cardonick, E. [10 ]
Denkert, C. [11 ,12 ]
Halaska, M. J. [13 ,14 ]
Hoeltzenbein, M. [15 ,16 ,17 ]
Johansson, A. L. V. [18 ,19 ]
Maggen, C. [20 ]
Markert, U. R. [21 ]
Peccatori, F. [22 ]
Poortmans, P. [23 ,24 ]
Saloustros, E. [25 ]
Saura, C. [26 ]
Schmid, P. [27 ]
Stamatakis, E. [28 ]
van den Heuvel-Eibrink, M. [29 ]
van Gerwen, M. [29 ,30 ,31 ,32 ]
Vandecaveye, V. [33 ]
Pentheroudakis, G. [34 ]
Curigliano, G. [35 ,36 ]
Amant, F. [30 ,37 ]
机构
[1] GBG Forsch GmbH, GBG, Neu Isenburg, Germany
[2] Ctr Haematol & Oncol Bethanien, Frankfurt, Germany
[3] Goethe Univ Frankfurt Main, Frankfurt, Germany
[4] Tecnol Monterrey, Breast Canc Ctr, Sch Med, San Pedro Garza Garcia, Nuevo Leon, Mexico
[5] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[6] Poissy St Germain Hosp, Dept Obstet & Gynecol, Poissy, France
[7] Paris Saclay Univ, BREED, RHuMA, INRAE,UMR 1198, Montigny Le Bretonneux, France
[8] Lund Univ, Dept Clin Sci, Div Oncol, Lund, Sweden
[9] Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden
[10] Rowan Univ, Cooper Med Sch, Camden, NJ USA
[11] Philipps Univ Marburg, Marburg, Germany
[12] Marburg Univ Hosp UKGM, Marburg, Germany
[13] Charles Univ Prague, Fac Med 3, Dept Gynaecol & Obstet, Prague, Czech Republic
[14] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic
[15] Charite Univ Med Berlin, Berlin, Germany
[16] Free Univ Berlin, Berlin, Germany
[17] Humboldt Univ, Inst Clin Pharmacol & Toxicol, Embryotox Ctr Clin Teratol & Drug Safety Pregnancy, Berlin, Germany
[18] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[19] Canc Registry Norway, Oslo, Norway
[20] Univ Hosp Brussels, Dept Obstet & Prenatal Med, Brussels, Belgium
[21] Jena Univ Hosp, Dept Obstet, Placenta Lab, Jena, Germany
[22] European Inst Oncol IRCCS, Dept Gynecol Oncol, Milan, Italy
[23] Iridium Netwerk, Antwerp, Belgium
[24] Univ Antwerp, Antwerp, Belgium
[25] Univ Hosp Larissa, Dept Gen Surg, Mezourlo, Larissa, Greece
[26] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain
[27] Queen Mary Univ London, Canc Inst, London, England
[28] Alexandra General Hosp, Dept Anesthesiol, Athens, Greece
[29] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[30] Antoni van Leeuwenhoek Netherlands Canc Inst, Gynecol Oncol, Amsterdam, Netherlands
[31] Univ Amsterdam, Dept Child & Adolescent Psychiat & Psychosocial Ca, Amsterdam UMC, Amsterdam, Netherlands
[32] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[33] Univ Hosp Leuven, Dept Radiol, Leuven, Belgium
[34] European Soc Med Oncol ESMO, Lugano, Switzerland
[35] Ist Ricovero & Cura Carattere Sci IRCCS, European Inst Oncol IEO, Div Gynecol Surg, Milan, Italy
[36] Univ Milan, Dept Oncol & Hemato Oncol, Milan, Italy
[37] UZ Leuven, Div Gynaecol Oncol, Leuven, Belgium
[38] GBG Forsch GmbH, German Breast Grp, Dornhofstr 10, D-63263 Neu Isenburg, Germany
关键词
(neo) adjuvant therapy; pregnancy management during cancer; pregnancy-related breast cancer; COLONY-STIMULATING FACTOR; MATERNAL CANCER; HEPATIC METASTASES; PRENATAL EXPOSURE; NEONATAL OUTCOMES; WOMEN; CHEMOTHERAPY; PROGNOSIS; FETAL; DIAGNOSIS;
D O I
10.1016/j.annonc.2023.08.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The management of breast cancer during pregnancy (PrBC) is a relatively rare indication and an area where no or little evidence is available since randomized controlled trials cannot be conducted. In general, advances related to breast cancer (BC) treatment outside pregnancy cannot always be translated to PrBC, because both the interests of the mother and of the unborn should be considered. Evidence remains limited and/or conflicting in some specific areas where the optimal approach remains controversial. In 2022, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process on this topic to gain insights from a multidisciplinary group of experts and develop statements on controversial topics that cannot be adequately addressed in the current evidence-based ESMO Clinical Practice Guideline. The aim of this consensus-building process was to discuss controversial issues relating to the management of patients with PrBC. The virtual meeting included a multidisciplinary panel of 24 leading experts from 13 countries and was chaired by S. Loibl and F. Amant. All experts were allocated to one of four different working groups. Each working group covered a specific subject area with two chairs appointed: 1. PrBC: incidence, epidemiology, biology and pathology, diagnostic work-up, staging and risk assessment, prognosis (Chairs: Vincent Vandecaveye, Fedro Peccatori). 2. Clinical pharmacology of systemic agents during pregnancy: management of localized disease and (neo) adjuvant therapies, management of systemic disease (Chairs: Giuseppe Curigliano, Peter Schmid). 3. Obstetric care and fetal/newborn follow-up and outcomes: metastases to fetus, management of pregnancy during anti-cancer therapy, lactation, psychological support (Chairs: Elyce Cardonick, Mathilde van Gerwen). Planning, preparation and execution of the consensus process was conducted according to the ESMO standard operating procedures.
引用
收藏
页码:849 / 866
页数:18
相关论文
共 138 条
[61]   Chemotherapy for ovarian cancer during pregnancy: A systematic review and meta-analysis of case reports and series [J].
Jiang, Xingzhi ;
Ye, Zhongxue ;
Yu, Wen ;
Fang, Qian ;
Jiang, Yafen .
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2021, 47 (10) :3425-3436
[62]   Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes [J].
Jindal, Sonali ;
Pennock, Nathan D. ;
Sun, Duanchen ;
Horton, Wesley ;
Ozaki, Michelle K. ;
Narasimhan, Jayasri ;
Bartlett, Alexandra Q. ;
Weinmann, Sheila ;
Goss, Paul E. ;
Borges, Virginia F. ;
Xia, Zheng ;
Schedin, Pepper .
NATURE COMMUNICATIONS, 2021, 12 (01)
[63]   Cancer survival in women diagnosed with pregnancy- associated cancer: An overview using nationwide registry data in Sweden 1970-2018 [J].
Johansson, Anna L., V ;
Fredriksson, Irma ;
Mellemkjaer, Lene ;
Stensheim, Hanne ;
Lahteenmaki, Paivi ;
Winther, Jeanette F. ;
Ullenhag, Gustav J. ;
Lundberg, Frida E. .
EUROPEAN JOURNAL OF CANCER, 2021, 155 :106-115
[64]   PARP1 during embryo implantation and its upregulation by oestradiol in mice [J].
Joshi, Anubha ;
Mahfooz, Sahil ;
Maurya, Vineet Kumar ;
Kumar, Vijay ;
Basanna, Chadchan Sangappa ;
Kaur, Gurpreet ;
Hanif, Kashif ;
Jha, Rajesh Kumar .
REPRODUCTION, 2014, 147 (06) :765-780
[65]   Radiotherapy during pregnancy: fact and fiction [J].
Kal, HB ;
Struikmans, H .
LANCET ONCOLOGY, 2005, 6 (05) :328-333
[66]   Deficiency of PARP-1 and PARP-2 in the mouse uterus results in decidualization failure and pregnancy loss [J].
Kelleher, Andrew M. ;
Setlem, Rohit ;
Dantzer, Francoise ;
DeMayo, Francesco J. ;
Lydon, John P. ;
Kraus, W. Lee .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (40)
[67]   Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis [J].
Kinkel, K ;
Lu, Y ;
Both, M ;
Warren, RS ;
Thoeni, RF .
RADIOLOGY, 2002, 224 (03) :748-756
[68]   Photon-beam radiotherapy in pregnant patients: Can the fetal dose be limited to 10 cGy or less? [J].
Kourinou, Kalliopi M. ;
Mazonakis, Michalis ;
Lyraraki, Efrossyni ;
Damilakis, John .
PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2015, 31 (01) :85-91
[69]  
Kujawa Emily, 2021, AANA J, V89, P291
[70]   TRANSIENT INCREASE IN THE RISK OF BREAST-CANCER AFTER GIVING BIRTH [J].
LAMBE, M ;
HSIEH, CC ;
TRICHOPOULOS, D ;
EKBOM, A ;
PAVIA, M ;
ADAMI, HO .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (01) :5-9